Multinational pharmaceutical companies compete with artificial intelligence in China and are they becoming important players?

When multinational pharmaceutical companies deploy artificial intelligence, which one is stronger and weaker?

Recently, IDEA Pharma and CNS released the CNS Summit Innovation Index TOP10, which is the fifth year since the list was released.
The "Annual Innovation and Invention Index" released by the institution in the first half of each year focuses on clinical trials and drug discovery.
The dimensions are different.
The list has added the indicator of commercialization.
Only companies that achieve a better balance in these three dimensions can be at the top of this list
.

The evaluation dimensions of this year’s CNS Summit Innovation Index ranking have also been updated from previous years.
“Digitalization and artificial intelligence” have also become an important factor affecting the ranking of enterprises.
IDEA Pharma and CNS believe that in the future, digital technology will be used to optimize clinical design, serve patients, and perform Drug discovery will become a new growth path for pharmaceutical companies in the future
.

It is worth noting that in this year’s TOP10, Pfizer, Johnson & Johnson, and Novartis are among the top three, while super-large pharmaceutical companies such as BMS, GSK, and Merck are not among them.
Instead, Amgen and Merck are not often on the list.
Of companies are among them.
Why? In addition, from the cooperation cases of major pharmaceutical companies, it is not difficult to find that the China region of Johnson & Johnson, Takeda and other companies is becoming an important participant in the cooperation, and China's role in the global layout of multinational pharmaceutical companies is also becoming more and more important
.

1.
Pfizer

1.
Pfizer

Pfizer has replaced Roche, who has been ranked first in the 2021 list, to the top of the list, raising three positions compared to last year
.

IDEA Pharma and CNS believe that the use of artificial intelligence technology in the development of the new crown vaccine has put Pfizer on the top, ranking fourth, second and first in terms of commercialization, clinical development, and drug discovery, respectively

The top three dimensions highlight Pfizer’s long-term growth potential.
Pfizer’s advanced market monitoring and data analysis capabilities are behind the estimated annual sales of tens of billions of dollars in vaccines.
In terms of digitalization, IDEA Pharma and CNS also affirmed Pfizer’s use of artificial intelligence.
The advancement of technology application in new drug research and development
.

For example, Pfizer established a cooperation with Itkos, a virtual drug related company, in March 2021 to better discover small molecule drugs and predict the success rate and development cycle of early drug development
.

Pfizer also reached a cooperation with IBM Watson as early as 2017, using the latter's supercomputing technology for cancer drug development
.

Pfizer can use the machine learning, natural language processing and cognitive reasoning capabilities of IBM Watson's Watson for Drug Discovery for new drug identification, combination therapy and patient selection strategies in immuno-oncology (Immuno-oncology)

It is worth noting that the great success of Pfizer in the new crown vaccine is also inseparable from the help of artificial intelligence technology.
In early 2020, Pfizer established a cooperation with Saama Technologies, an artificial intelligence clinical analysis platform company, to develop a clinical trial based on artificial intelligence technology.
Data management and detection platform, using the latter technology, Pfizer provides real-world data and expertise to help Saama Technologies learn
.

The platform finally achieved clinical data collation and error identification within 24 hours with minimal human intervention, which promoted the clinical development of Pfizer's new crown vaccine

2.
Johnson & Johnson

2.
Johnson & Johnson

Johnson & Johnson’s revenue in the third quarter was 23 billion US dollars, a year-on-year increase of 10.
7%.
Compared with the same period last year, the device business increased by 8%, the consumer health business increased by 5.
2%, and the drug sales increased by 13.
8%
.

The reason why IDEA Pharma and CNS give such a high evaluation lies in the several collaborations between Johnson & Johnson and the artificial intelligence platform

Johnson & Johnson has always been committed to becoming a giant in the field of surgical robotics.

It acquired Auris Health for $3.

In the third quarter, Johnson & Johnson announced that its soft tissue robot Ottava will postpone its entry into the market for two years for differentiated upgrades
.

Another major cooperation in the field of artificial intelligence is the collaboration between Janssen and Insilico Medicine, an AI drug research and development company
.

According to the agreement between the two parties, Insilico Medicine will design small molecules with specific properties for the target proposed by Janssen, and receive advance payment and milestone payment

In addition, during the 2020 CIIE, the cooperation between Johnson & Johnson, Shanghai Diannei Biotech and Taikang Online has also been paid attention to by IDEA Pharma and CNS.
It is believed that these three strategic cooperations are Johnson & Johnson’s rise from the third place in the 2020 Innovation Index to An important factor for second place
.

3.
Novartis

3.
Novartis

"Novartis has jumped three places in the 2021 index, making it one of the top innovative drug companies
.

" IDEA Pharma and CNS evaluation

Previously, Novartis had reached a cooperation with digital healthcare company Cievert, which helped Novartis collect and count patient data and manage patients
.

In terms of artificial intelligence, Novartis also cooperated with Elsevier to conduct risk assessment of adverse drug reactions through artificial intelligence technology

4.
Eli Lilly

4.
Eli Lilly

Eli Lilly's applications in the digital field are mainly concentrated in the field of diabetes.
One is to use artificial intelligence for disease management, and the other is to use artificial intelligence to drive drug research and development
.

In 2021, Eli Lilly and WellDoc announced a partnership.
Through a program run by WellDoc, Eli Lilly launched a networked insulin pen that connects various blood glucose meters and continuous glucose monitoring systems to provide insulin for adult patients with type 1 or type 2 diabetes.
Titration support, high-dose calculator and personalized health guidance
.
The cooperation is expected to submit an application to the FDA within this year
.

Another collaboration of Eli Lilly in the field of diabetes is the collaboration with Biolojic, a biotechnology company that designs functional antibodies.
Eli Lilly will be able to use Biolojic's AI-based multi-antibody platform to discover and develop antibody-based diabetes treatments
.
By using AI, Biolojic can design and develop new types of therapeutic antibodies with new mechanisms of action, including multi-antibody-multi-specific symmetric IgG mAb and epitope-specific antibodies
.
These antibodies can affect multiple targets in different tissues at different times and precisely control the function of each target
.
Biolojic's product line focuses on epitope specificity and dual targets that are the key targets and therapies to improve efficacy
.

In addition, Eli Lilly also cooperates with DexCom, Glooko Inc.
, myDiabby Healthcare and other companies to use artificial intelligence technology for patient management
.

5.
Amgen

5.
Amgen

What Amgen attracted the attention of IDEA Pharma and CNS were two collaborations on heart failure
.

The first is a collaboration with Datos Health, which aims to use the latter’s technology to organize patients’ health data, thereby improving the dose of heart failure therapy; the second collaboration is to cooperate with Liva Healthcar to provide improved cardiac rehabilitation services, so that the heart Patients after the onset of illness can receive cardiac rehabilitation services
.
This collaboration will enable the two companies to develop Rehab+, a digital remote rehabilitation solution that allows patients to evaluate their life>
.

In addition, Amgen is also using machine learning to develop innovative drugs.
Amgen’s partner GNS Healthcare’s AI technology integrates and transforms various types of patient data into a virtual patient to simulate disease progression and drug response
.
This virtual patient can be used as an assistive technology platform for clinical trial design and real-world evidence generation
.
On August 23, 2017, Amgen's investment arm led the investment of GNS Healthcare's US$6 million financing
.

6.
Roche

6.
Roche

Roche ranked first in the 2020 list and dropped a full five places this year, but this does not deny his application in the field of artificial intelligence
.

The diagnostic business has always been a non-negligible part of Roche’s revenue.
In the pandemic of the new coronavirus, Roche has not only become a member of the home nucleic acid testing equipment provider, but also provides its Navify Pass digital solutions to allow users to pass their personalities.
The customized QR code stores, displays and shares their COVID-19 test results and vaccine status
.

In terms of diabetes, as early as 2017, Roche acquired the diabetes management platform mySugar.
Through this platform, patients can record their illnesses in a timely manner and upload the data to doctors and insurance companies to obtain timely diagnosis and treatment and insurance plans
.

7.
BI

7.
BI

BI's ranking suddenly rose from last year's 14th to seventh, because of the application of its digital research program centered on artificial intelligence and quantum computing technology
.

In 2019, BI announced a collaboration with Science 37, a leading company in the virtual clinical trial industry.
Science 37 authorized access to its proprietary software platform, Network Oriented Research Assistant.
Participate in clinical trials in case of location
.
This new collaboration combines Science 37's technology for remote clinical trials and Boehringer Ingelheim's extensive capabilities in drug discovery and clinical development of new therapies
.

In 2021, BI and Google’s quantum computing department have reached a cooperation.
The two parties will focus on researching and realizing cutting-edge application cases of quantum computing in the field of drug research and development, especially in the field of molecular dynamics simulation
.
Based on this new collaboration, Boehringer Ingelheim will combine its leading expertise in computer-aided drug design and computer simulation with the outstanding resources of Google, a leading developer of quantum computers and algorithms
.
Boehringer Ingelheim will become the world's first pharmaceutical company to cooperate with Google in the field of quantum computing
.

These two collaborations have brought BI's digital drug R&D capabilities to the attention of IDEA Pharma and CNS
.

8.
Takeda

8.
Takeda

The reason why Takeda has attracted much attention comes from its cooperation in China
.

In March 2021, Takeda China announced the official launch of TakedaSpark, an open incubation and innovation platform, Takeda China's innovation incubator, to accelerate the co-creation of digital medical future solutions and innovative business service models
.
The incubator will integrate industry innovation opportunities, combine cutting-edge technologies such as artificial intelligence, machine learning, and smart devices to scientifically improve disease screening efficiency and detection accuracy, and further promote the practice and promotion of precision medicine; based on the advantages and characteristics of Takeda’s innovative drugs, it will create "Beyond the Pill" digital healthcare; build big data analysis and algorithm capabilities, use big data to insight into doctors and patients' needs, improve precision marketing tools and improve efficiency, and achieve results at the strategic commanding heights of real-world data
.
The "Newborn Wearable Program" is the first project of this incubator, which aims to use blue light sensor technology to accurately measure the baby's jaundice and bilirubin levels
.

9.
AstraZeneca

9.
AstraZeneca

AstraZeneca's performance in the field of digitalization and artificial intelligence is not outstanding.
It is optimizing clinical trial design through its own AMAZE platform, monitoring real-world data, and optimizing communication between patients and medical teams
.

In addition, AstraZeneca also cooperates with digital medical company AliveCor to use the latter's Kardia-K AI technology to perform "non-invasive" monitoring, measure potassium levels without drawing blood, and establish new cardiovascular, renal and metabolic diseases.
Management method
.

10.
Merck, Germany

10.
Merck, Germany

The company is cooperating with Neuroloop GmbH, a subsidiary of German Braun, to explore the use of neurostimulation technology to treat some unmet clinical needs
.

In addition, Merck has also reached an artificial intelligence drug research and development cooperation with Itkos, which aims to automatically design virtual new molecules for the targeted development of a variety of diseases
.

This article is compiled from IDEA Pharma "CNS Summit Innovation Index 2021"

This article is compiled from IDEA Pharma "CNS Summit Innovation Index 2021"